CureVac N.V. (CVAC)

CureVac N.V. was a biopharmaceutical company that developed medicines and vaccines based on messenger RNA (mRNA). It was founded in 2000 in Tübingen, Germany, and was one of the early companies to pursue mRNA as a platform for vaccines and therapeutics. The company later became a Dutch public limited company, N.V., while keeping its operations and headquarters in Tübingen.

The business focused on prophylactic vaccines, cancer immunotherapies and molecular therapies, and it developed manufacturing capability for mRNA products. CureVac relied on collaborations with larger pharmaceutical and biotechnology companies to fund research, including agreements with GSK for infectious disease vaccines and with Genmab for oncology antibody programs. Funding from the German government and other public sources also supported its COVID-19 vaccine work.

CureVac completed its initial public offering on the Nasdaq Global Select Market in August 2020 under the symbol CVAC, raising several hundred million dollars. Its first COVID-19 vaccine candidate, CVnCoV, reached late-stage trials in 2021 but showed lower efficacy than competing mRNA vaccines, and the program was ultimately discontinued. The company then shifted attention to second-generation vaccines developed with GSK and to its oncology pipeline.

In 2024 CureVac and GSK restructured their licensing arrangements for vaccine programs, and the company reorganized to concentrate on its core research efforts. The company continued to report net losses, and its prospects depended on advancing its clinical candidates and on partner payments. Competitors in the field included larger commercial mRNA companies with established revenue.

On June 12, 2025, BioNTech SE announced plans to acquire CureVac in an all-stock transaction through a public exchange offer. The combination was intended to bring together two German mRNA companies and to consolidate overlapping intellectual property and development work. BioNTech, which is listed on Nasdaq under the symbol BNTX, offered its American depositary shares in exchange for CureVac shares.

After the exchange offer settled, CureVac completed a post-offer reorganization on January 6, 2026. According to the company's SEC filing, BioNTech then became the sole owner of CureVac's business operations, and no public shareholders continued to hold CureVac shares. CureVac asked Nasdaq to suspend trading before the market opened on January 6 and requested that a Form 25 be filed to delist and deregister the shares under Section 12(b) of the Exchange Act. Delisting was expected to become effective in mid-January 2026.

Following the Form 25, CureVac Merger B.V. planned to file a Form 15 to end registration under Section 12(g) and suspend reporting obligations, with deregistration taking effect about 90 days later. The CVAC ticker is no longer traded, and CureVac's operations and programs are now part of the BioNTech group.